...
首页> 外文期刊>Journal of Clinical Microbiology >Detection of hepatitis C virus by PCR in second-generation enzyme immunoassay-seropositive blood donors by using matched pairs of fresh frozen plasma and pilot tube sera.
【24h】

Detection of hepatitis C virus by PCR in second-generation enzyme immunoassay-seropositive blood donors by using matched pairs of fresh frozen plasma and pilot tube sera.

机译:通过使用配对的新鲜冷冻血浆和中试管血清对,在第二代酶免疫测定血清反应阳性献血者中通过PCR检测丙型肝炎病毒。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Between April 1993 and March 1995, 429 of 334,454 (0.13%) blood donations at the Toronto Centre of the Canadian Red Cross were reactive for hepatitis C virus (HCV) by second-generation enzyme immunoassay (EIA-2). Of the 429 EIA-2-positive donations, 189 (44%), 138 (32%), and 102 (24%) were positive, indeterminate, and negative by Second-Generation Recombinant Immunoblot Assay (RIBA-2). To assess HCV viremia and minimize the risk that specimen handling affected PCR-based detection, the qualitative AMPLICOR HCV test was performed on both pilot tube sera (PTS) and the corresponding fresh frozen plasma (FFP) from 294 EIA-2-reactive donations. AMPLICOR PCR results for PTS and FFP were 100% concordant and were confirmed by nested HCV PCR for 27 of 294 donations. The AMPLICOR HCV test was positive for 127 of 140 (91%) of RIBA-2-positive donations (81, 91, and 96% of donations with two, three, and four reactive bands, respectively), 5 of 88 (5.7%) indeterminate donations, and 0 of 66 (0%) RIBA-2-negative donations. The Third-Generation Recombinant Immunoblot Assay (RIBA-3) was performed on RIBA-2-negative, -indeterminate, and -positive, PCR-negative donations. RIBA-3 demonstrated enhanced specificity and resolved 18 of 88 (20%) of RIBA-2-indeterminate samples as HCV antibody positive. The study demonstrates that PTS are as suitable as FFP for PCR-based detection of HCV and can be used to determine if EIA-2-reactive blood donors are viremic at the time of donation.
机译:在1993年4月至1995年3月之间,通过第二代酶免疫分析(EIA-2),加拿大红十字会多伦多中心的334,454例无偿献血中有429例对丙型肝炎病毒(HCV)有反应。在第二代重组免疫印迹分析(RIBA-2)中,在EIA-2阳性429例中,有189例(44%),138例(32%)和102例(24%)为阳性,不确定和阴性。为了评估HCV病毒血症并最大程度地减少样本处理影响基于PCR的检测的风险,对来自294个EIA-2反应性捐赠者的先导试管血清(PTS)和相应的新鲜冷冻血浆(FFP)进行了定性AMPLICOR HCV测试。 PTS和FFP的AMPLICOR PCR结果100%一致,并且通过嵌套HCV PCR对294份捐赠中的27份进行了确认。 AMPLICOR HCV测试显示RIBA-2阳性捐赠140项中有127项呈阳性(91%)(分别有两个,三个和四个反应带的捐赠中有81%,91%和96%),88项中有5项(5.7%) )不确定的捐款,以及RIBA-2阴性捐款中的0(共66个,占0%)。对RIBA-2阴性,不确定和阳性PCR阴性的捐赠者进行了第三代重组免疫印迹分析(RIBA-3)。 RIBA-3表现出更高的特异性,并在88例(20%)RIBA-2不确定样本中解析为HCV抗体阳性。该研究表明,PTS与FFP一样适合用于基于PCR的HCV检测,并可用于确定EIA-2反应性献血者在献血时是否有病毒血症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号